Close X
Attorney Spotlight

What emerging trend in shareholder litigation does Britt Latham find most interesting in his practice today?    Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

Envision to Sell to KKR for $9.9 Billion

We represented Envision Healthcare Corporation (NYSE: EVHC) in its definitive agreement to sell to KKR in an all-cash transaction for $9.9 billion, including debt. KKR will pay $46 per Envision share in cash to buy the company, marking a 32 percent premium to the company's volume-weighted average share price from November 1, when Envision announced it was considering its options. The transaction is expected to close the fourth quarter of 2018. Read more


Envision Healthcare

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Six Things to Know Before Buying a Physician Practice spotlight

Dermatology, ophthalmology, radiology, urology…the list goes on. Yet, in any physician practice management transaction, there are six key considerations that apply and, if not carefully managed, can derail a transaction. Download the 6 Things to Know Before Buying a Physician Practice to keep your physician practice management transactions on track.

Click here to download the guide.

How to Implement Effective Internal Controls to Prevent Corrupt Behavior and Minimize the Risks of Third Party Bribes in Foreign Clinical Research

Events

May 9, 2012

Bass, Berry & Sims FCPA and healthcare fraud attorney, John Kelly, will co-present "How to Implement Effective Internal Controls to Prevent Corrupt Behavior and Minimize the Risks of Third Party Bribes in Foreign Clinical Research" at the American Conference Institute's 6th Annual Conference on FCPA and Anti-Corruption for the Life Sciences Industry. Co-presenters include Clivetty Martinez, Health Care Compliance & Privacy Johnson & Johnson International, Inc., and Joseph Alesia, Senior Counsel, Ethics and Compliance/Legal for Baxter International Inc.

The presentation will cover:

  • Best practices for monitoring actions undertaken by HCPs, CROs, third parties and other consultants when interacting with local government officials during the clinical research process
    • how to establish procedures for ensuring local procedures are followed without exposing the company to potential FCPA violations -
    • establishing internal controls to detect and prevent local anti-bribery issues, particularly within foreign clinical research, sales and distribution operations – investigator, health ministry approval, patient payments
  • Distinguishing parameters for locally-accepted/expected "grease payments" vs. what is permissible under the FCPA – knowing where to draw the line regarding what does/does not qualify as a facilitation payment
  • Striking the balance between too much vs. too little oversight when managing and overseeing operations led by local third parties
  • UK Bribery Act - how companies are updating global compliance programs to address facilitation payments across international life sciences operations

Bass, Berry & Sims is proud to be a sponsor of this conference.

Download Document - FCPA and Anti-Corruption for the Life Sciences Industry Conference Brochure

In Case You Missed It:

Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.